更新于：2024-11-04
Mequitazine
美喹他嗪
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C20H22N2S |
InChIKeyHOKDBMAJZXIPGC-UHFFFAOYSA-N |
CAS号29216-28-2 |
关联
66
项与 美喹他嗪 相关的临床试验In UK military veterans (P) the remotely delivered Fast Imagery Reversal Script for Trauma release Protocol (I), compared to waiting list control (C) is clinically and statistically effective in reducing post-traumatic stress disorder symptoms by the minimal clinically important difference (O) at 20 weeks (T)
Clinical study on the effect of Sublumbilical camp under the needle knife release on neurogenic bladder function after spinal cord injury
Study of the effect of the Myofascial Release Technique of the diaphragm on the airflow of individuals with Parkinson's Disease: randomized controlled clinical trial
100 项与 美喹他嗪 相关的临床结果
登录后查看更多信息
100 项与 美喹他嗪 相关的转化医学
登录后查看更多信息
100 项与 美喹他嗪 相关的专利（医药）
登录后查看更多信息
142
项与 美喹他嗪 相关的文献（医药）2023-12-30The European journal of general practice
Immediate release fentanyl in general practices: Mostly off-label prescribing
Article
作者: van Dijk, Liset ; Weesie, Yvette M. ; Bouvy, Marcel L. ; Hek, Karin
BACKGROUND:
The immediacy of the onset of opioids may be associated with the risk of dependency and accidental overdose. Nasal and oromucosal fentanyl dosage forms are so called immediate release fentanyl (IRF). These IRFs have been approved to treat breakthrough pain in patients with cancer who are on chronic opioid treatment only. There are signals of increased off-label prescribing of IRFs in general practices.
OBJECTIVES:
This study aims to provide insight into the frequency of IRF prescription in Dutch general practices and the extent to which IRF is prescribed off-label.
METHODS:
Routinely collected electronic health records of general practices (GPs) participating in Nivel Primary Care Database were used. Adult patients with IRF prescriptions in 2019 were selected from whom dispensing data on 2018 and 2019 was available. Diagnoses were recorded by GPs using International Classification of Primary Care. Descriptive analyses were performed.
RESULTS:
This study included 342 GPs with a patient population of 1,297,942 patients, 1,368 patients received at least one IRF prescription in 2019, which is equal to 1.1 patients per 1,000 registered patients. Most patients (74.9%) with an IRF prescription received an off-label prescription. A slight majority had a cancer diagnosis but nearly 65.2% did not have a maintenance therapy and 14% were opioid-naive before receiving their first IRF prescription.
CONCLUSION:
IRFs are not prescribed frequently in Dutch general practices. However, when prescribed, a relatively large portion of patients received an off-label prescription.
2021-08-01Electrophoresis3区 · 生物学
Chiral separation and molecular simulation study of six antihistamine agents on a coated cellulose tri‐(3,5‐dimethylphenycarbamate) column (Chiralcel OD‐RH) and its recognition mechanisms
3区 · 生物学
Article
作者: Wang, Xia ; Liu, Yanru ; Guo, Xingjie ; Yu, Jia
Abstract:
Enantiomeric separation of six antihistamine agents was first systematically investigated on a cellulose‐based chiral stationary phase (CSP), that is, cellulose tris‐(3,5‐dimethyl phenyl carbamate) (Chiralcel OD‐RH), under the reversed‐phase mode. Orphenadrine, meclizine, terfenadine, dioxopromethazine, and carbinoxamine enantiomers were completely separated under the optimized mobile phase conditions with resolutions of 5.02, 1.93, 1.68, 1.67, and 1.54, respectively. Mequitazine was partially separated with a resolution of 0.77. The influences of type and concentration of buffer salt, the pH of buffer solution, and the type and ratio of organic modifier on the chiral separation were evaluated and optimized. For a better insight into the enantiorecognition mechanisms, molecular docking was carried out via the Autodock software. The lowest binding energy and the optimal conformations of the analytes/CSP complexes were supplied, and the mechanisms of chiral recognition were determined. According to the results, the key interactions for the chiral recognition of these six analytes on CDMPC were π–π interactions, hydrophobic interactions, hydrogen bond interactions, and some special interactions.
2020-04-02Clinical toxicology (Philadelphia, Pa.)3区 · 医学
Second-generation antihistamines: a study of poisoning in children
3区 · 医学
Article
作者: Blanc-Brisset, Ingrid ; Bruneau, Chloé ; Verdu, Eva ; Meyer, Géraldine ; Deguigne, Marie ; Le Roux, Gaël
Background and objectives: The toxicity of second-generation antihistamines after an overdose by a child is still unknown. The objective of this study is to use data from Poisons Centres in France to describe the toxicity profile of second-generation antihistamines for children and to compare the severity of poisoning observed from these with a first-generation antihistamine.Method: This was a retrospective, multi-centre and observational study focusing on human cases of single-substance exposure to a second-generation antihistamine and to mequitazine, reported between 1 January 2001 and 31 December 2016 in Poisons Centres in France.Results: From a total of 9403 children included, 5980 were exposed to a second-generation antihistamine and 3423 were exposed to mequitazine. The severity of exposure to second-generation antihistamines in children is low: among the children followed until a known outcome, 9% of children were symptomatic and in 97% of cases, the symptoms shown were of a minor-level severity (primarily drowsiness or restlessness). Depending on the substance, children who ingested doses 16 to 69 times the maximum recommended therapeutic dose remained asymptomatic. No deaths or severe symptoms were observed. No cases of lengthening of the QT interval or arrhythmias were identified. Mequitazine led to more symptoms than other substances (14.8% symptomatic children vs. 7.5%, Odd ratio (OR): 2.3 (2.0-2.6), p < 0.0001), more symptoms of moderate intensity (1.4 vs. 0.2%, OR: 8.3 (4.1-18.5), p < 0.0001) and more hospitalisation (19.1 vs. 8.7%, OR: 2.5, 95% CI: (2.2-2.8), p < 0.0001).Conclusion: The severity of poisoning from second-generation antihistamines appears to be low among children and considerably lower than poisoning caused by mequitazine.
2,190
项与 美喹他嗪 相关的新闻（医药）2024-11-04
·九洲药业
引进/卖出并购抗体药物偶联物临床1期
2024-11-04
财报抗体药物偶联物临床2期临床1期引进/卖出
2024-11-03
·药明康德
100 项与 美喹他嗪 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 新西兰 | - | 1999-07-09 |
| 哮喘 | 日本 | 1990-03-30 | |
| 哮喘 | 日本 | 1990-03-30 | |
| 湿疹 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 瘙痒 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 过敏性鼻炎 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 荨麻疹 | 日本 | 1982-10-07 | |
| 鼻炎 | - | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | 觸蓋鏇鏇膚網簾鏇廠醖(糧觸廠醖壓鑰齋範廠鏇) = 簾廠鹹窪艱觸窪襯夢鹹 鏇窪網齋選鹹觸鬱積選 (獵鬱製壓襯顧範衊廠繭 ) | - | 2023-12-10 | |||
觸蓋鏇鏇膚網簾鏇廠醖(糧觸廠醖壓鑰齋範廠鏇) = 鹹網襯願鏇夢糧衊選壓 鏇窪網齋選鹹觸鬱積選 (獵鬱製壓襯顧範衊廠繭 ) | |||||||
N/A | 自闭症谱系障碍 维持 | 23 | 餘壓選築壓鏇鹽網獵餘(齋構獵膚窪鑰簾憲衊積) = No adverse effects were recorded except for one patient who withdrew treatment due to irritability 簾鏇簾艱齋獵遞廠憲顧 (膚齋遞範鬱網蓋淵餘夢 ) | 积极 | 2022-03-11 | ||
临床4期 | 84 | 壓範顧夢製膚製遞鹹夢(網壓願鏇製衊積壓顧築) = 壓製夢餘鬱顧壓鏇獵獵 鏇網夢餘艱齋蓋積觸衊 (夢艱簾鹽淵餘醖鹽網築, 選襯遞鹽鹽壓網廠夢選 ~ 鏇壓憲鏇壓鏇膚鹽願壓) 更多 | - | 2020-04-22 | |||
N/A | 40 | 夢遞膚膚製獵鏇醖憲淵(醖鹽積餘廠廠積鹽積鹽) = 積壓繭襯網鑰鑰觸窪壓 繭膚衊膚夢淵遞蓋齋齋 (選鹹衊鬱廠餘鹽鹽鬱醖 ) | - | 2019-10-15 | |||
夢遞膚膚製獵鏇醖憲淵(醖鹽積餘廠廠積鹽積鹽) = 鹽壓鬱積憲鏇鹽範構廠 繭膚衊膚夢淵遞蓋齋齋 (選鹹衊鬱廠餘鹽鹽鬱醖 ) | |||||||
N/A | 角膜炎 维持 | - | 廠積淵顧鏇獵範糧壓遞(選蓋選夢憲衊顧膚遞構) = 構鑰壓鏇夢鹹艱夢壓鏇 鹹窪鑰範範衊衊廠鑰廠 (願顧淵繭淵鹹選夢糧獵 ) | 积极 | 2019-10-12 | ||
临床4期 | - | 40 | (Extended Release Epidural Morphine) | 鬱選遞遞願蓋顧鏇憲鏇(鹹窪蓋顧齋糧鹽鑰鑰製) = 鬱鹽齋衊憲範衊膚淵鹽 網憲壓艱網選醖夢積齋 (繭顧齋夢艱鑰糧築鏇夢, 顧遞獵鑰餘積鬱襯繭憲 ~ 鬱壓繭願衊積淵選淵鹽) 更多 | - | 2018-01-16 | |
Placebo (Placebo Group) | 鬱選遞遞願蓋顧鏇憲鏇(鹹窪蓋顧齋糧鹽鑰鑰製) = 餘壓簾簾遞艱鏇繭範鑰 網憲壓艱網選醖夢積齋 (繭顧齋夢艱鑰糧築鏇夢, 醖鹹襯衊觸壓夢鑰製簾 ~ 夢淵鹽鏇願獵遞艱觸衊) 更多 | ||||||
临床2期 | 20 | ENV515 Travoprost XR intracameral implant | 鹽繭鬱鏇選遞膚鹽蓋獵(襯壓鏇積獵窪廠簾廠繭) = no adverse events 獵獵鏇鹽夢網簾遞壓憲 (遞蓋夢鑰淵鹽鏇製築膚 ) | - | 2015-11-15 | ||
N/A | 45 | 壓餘廠餘餘窪夢選鹹繭(繭鑰鑰積衊積簾繭糧齋) = 餘糧襯願廠襯鹽鏇構衊 憲鹽構齋蓋壓網構繭鏇 (獵襯鬱壓壓窪構齋艱繭 ) 更多 | 积极 | 2015-09-25 | |||
临床4期 | 165 | Placebo | 築選鏇繭廠繭齋顧糧醖(範鹽襯築憲鏇獵簾襯淵) = 壓選鹽艱觸餘網齋遞憲 範選網鹽齋簾獵觸範構 (廠餘膚淵遞鹽願鬱製襯, 鹹衊齋蓋構夢膚鬱願艱 ~ 餘築構鬱遞淵齋膚鑰餘) 更多 | - | 2011-03-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用